New York, New York--(Newsfile Corp. - May 12, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ChemoCentryx, Inc. (NASDAQ: CCXI) alleging that the Company violated federal securities laws.
Class Period: November 26, 2019 and May 3, 2021
Lead Plaintiff Deadline: July 6, 2021
Learn more about your recoverable losses in CCXI:
The filed complaint alleges that ChemoCentryx, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Shareholders have until July 6, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
For additional information about the CCXI lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83759